TSplus Introduces New Feedback & Roadmap Platform to Enhance the Remote Desktop User Experience
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration
FUTR Announces Q1 2026 Financial Results
Tenet Reports Third Quarter 2025 Financial Results
Eguana Announces Third Quarter 2025 Financial Results
FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:…
FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:…
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a…
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a…
FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth…
FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth…
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc….
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc….
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology…
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology…
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company…
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company…
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date…
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date…
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of…
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of…
ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company”…
ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company”…